148 related articles for article (PubMed ID: 20605676)
1. Up-regulation of death receptor 4 and 5 by celastrol enhances the anti-cancer activity of TRAIL/Apo-2L.
Zhu H; Liu XW; Ding WJ; Xu DQ; Zhao YC; Lu W; He QJ; Yang B
Cancer Lett; 2010 Nov; 297(2):155-64. PubMed ID: 20605676
[TBL] [Abstract][Full Text] [Related]
2. Down-regulation of Cbl-b by bufalin results in up-regulation of DR4/DR5 and sensitization of TRAIL-induced apoptosis in breast cancer cells.
Yan S; Qu X; Xu C; Zhu Z; Zhang L; Xu L; Song N; Teng Y; Liu Y
J Cancer Res Clin Oncol; 2012 Aug; 138(8):1279-89. PubMed ID: 22447040
[TBL] [Abstract][Full Text] [Related]
3. Pretreatment with paclitaxel enhances apo-2 ligand/tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis of prostate cancer cells by inducing death receptors 4 and 5 protein levels.
Nimmanapalli R; Perkins CL; Orlando M; O'Bryan E; Nguyen D; Bhalla KN
Cancer Res; 2001 Jan; 61(2):759-63. PubMed ID: 11212279
[TBL] [Abstract][Full Text] [Related]
4. Synergistic anti-cancer activity by the combination of TRAIL/APO-2L and celastrol.
Zhu H; Ding WJ; Wu R; Weng QJ; Lou JS; Jin RJ; Lu W; Yang B; He QJ
Cancer Invest; 2010 Jan; 28(1):23-32. PubMed ID: 19916747
[TBL] [Abstract][Full Text] [Related]
5. Celastrol enhances TRAIL-induced apoptosis in human glioblastoma via the death receptor pathway.
Cha Z; Cheng J; Xiang H; Qin J; He Y; Peng Z; Jia J; Yu H
Cancer Chemother Pharmacol; 2019 Oct; 84(4):719-728. PubMed ID: 31281953
[TBL] [Abstract][Full Text] [Related]
6. Ursolic acid, a pentacyclin triterpene, potentiates TRAIL-induced apoptosis through p53-independent up-regulation of death receptors: evidence for the role of reactive oxygen species and JNK.
Prasad S; Yadav VR; Kannappan R; Aggarwal BB
J Biol Chem; 2011 Feb; 286(7):5546-57. PubMed ID: 21156789
[TBL] [Abstract][Full Text] [Related]
7. Azithromycin enhances anticancer activity of TRAIL by inhibiting autophagy and up-regulating the protein levels of DR4/5 in colon cancer cells in vitro and in vivo.
Qiao X; Wang X; Shang Y; Li Y; Chen SZ
Cancer Commun (Lond); 2018 Jul; 38(1):43. PubMed ID: 29970185
[TBL] [Abstract][Full Text] [Related]
8. Lipocalin 2 inversely regulates TRAIL sensitivity through p38 MAPK-mediated DR5 regulation in colorectal cancer.
Kim SL; Min IS; Park YR; Lee ST; Kim SW
Int J Oncol; 2018 Dec; 53(6):2789-2799. PubMed ID: 30221676
[TBL] [Abstract][Full Text] [Related]
9. Kaempferol Sensitizes Human Ovarian Cancer Cells-OVCAR-3 and SKOV-3 to Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand (TRAIL)-Induced Apoptosis via JNK/ERK-CHOP Pathway and Up-Regulation of Death Receptors 4 and 5.
Zhao Y; Tian B; Wang Y; Ding H
Med Sci Monit; 2017 Oct; 23():5096-5105. PubMed ID: 29070784
[TBL] [Abstract][Full Text] [Related]
10. Lipoxygenase inhibitor MK886 potentiates TRAIL-induced apoptosis through CHOP- and p38 MAPK-mediated up-regulation of death receptor 5 in malignant glioma.
Woo JS; Kim SM; Jeong CH; Ryu CH; Jeun SS
Biochem Biophys Res Commun; 2013 Feb; 431(2):354-9. PubMed ID: 23261452
[TBL] [Abstract][Full Text] [Related]
11. Pro-survival effects by NF-κB, Akt and ERK(1/2) and anti-apoptosis actions by Six1 disrupt apoptotic functions of TRAIL-Dr4/5 pathway in ovarian cancer.
Yang J; Li G; Zhang K
Biomed Pharmacother; 2016 Dec; 84():1078-1087. PubMed ID: 27780136
[TBL] [Abstract][Full Text] [Related]
12. Cotreatment with histone deacetylase inhibitor LAQ824 enhances Apo-2L/tumor necrosis factor-related apoptosis inducing ligand-induced death inducing signaling complex activity and apoptosis of human acute leukemia cells.
Guo F; Sigua C; Tao J; Bali P; George P; Li Y; Wittmann S; Moscinski L; Atadja P; Bhalla K
Cancer Res; 2004 Apr; 64(7):2580-9. PubMed ID: 15059915
[TBL] [Abstract][Full Text] [Related]
13. Accumulation of autophagosomes in breast cancer cells induces TRAIL resistance through downregulation of surface expression of death receptors 4 and 5.
Di X; Zhang G; Zhang Y; Takeda K; Rivera Rosado LA; Zhang B
Oncotarget; 2013 Sep; 4(9):1349-64. PubMed ID: 23988408
[TBL] [Abstract][Full Text] [Related]
14. Upregulation of microRNA135a-3p and death receptor 5 plays a critical role in Tanshinone I sensitized prostate cancer cells to TRAIL induced apoptosis.
Shin EA; Sohn EJ; Won G; Choi JU; Jeong M; Kim B; Kim MJ; Kim SH
Oncotarget; 2014 Jul; 5(14):5624-36. PubMed ID: 25015549
[TBL] [Abstract][Full Text] [Related]
15. Celastrol, a triterpene, enhances TRAIL-induced apoptosis through the down-regulation of cell survival proteins and up-regulation of death receptors.
Sung B; Park B; Yadav VR; Aggarwal BB
J Biol Chem; 2010 Apr; 285(15):11498-507. PubMed ID: 20154087
[TBL] [Abstract][Full Text] [Related]
16. The proteasome inhibitor PS-341 (bortezomib) up-regulates DR5 expression leading to induction of apoptosis and enhancement of TRAIL-induced apoptosis despite up-regulation of c-FLIP and survivin expression in human NSCLC cells.
Liu X; Yue P; Chen S; Hu L; Lonial S; Khuri FR; Sun SY
Cancer Res; 2007 May; 67(10):4981-8. PubMed ID: 17510429
[TBL] [Abstract][Full Text] [Related]
17. CAPE promotes TRAIL-induced apoptosis through the upregulation of TRAIL receptors via activation of p38 and suppression of JNK in SK-Hep1 hepatocellular carcinoma cells.
Kim EY; Ryu JH; Kim AK
Int J Oncol; 2013 Oct; 43(4):1291-300. PubMed ID: 23857473
[TBL] [Abstract][Full Text] [Related]
18. DR4 specific TRAIL variants are more efficacious than wild-type TRAIL in pancreatic cancer.
Yu R; Albarenque SM; Cool RH; Quax WJ; Mohr A; Zwacka RM
Cancer Biol Ther; 2014; 15(12):1658-66. PubMed ID: 25482930
[TBL] [Abstract][Full Text] [Related]
19. Prediction of proapoptotic anticancer therapeutic response in vivo based on cell death visualization and TRAIL death ligand-receptor interaction.
Zhou L; Wang W; Dicker DT; Humphreys RC; El-Deiry WS
Cancer Biol Ther; 2011 Aug; 12(4):335-48. PubMed ID: 21785270
[TBL] [Abstract][Full Text] [Related]
20. Molecular determinants of epothilone B derivative (BMS 247550) and Apo-2L/TRAIL-induced apoptosis of human ovarian cancer cells.
Griffin D; Wittmann S; Guo F; Nimmanapalli R; Bali P; Wang HG; Bhalla K
Gynecol Oncol; 2003 Apr; 89(1):37-47. PubMed ID: 12694652
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
